Obesity is treated as a chronic disease because body weight is defended by biology, its causes go well beyond willpower, and its health effects usually return when treatment stops. That is why care is framed as long-term management, not a short fix.
Obesity is treated as a chronic disease because the body actively defends its weight, the causes are many and only partly within a person's control, and the health effects tend to return when treatment stops. Major medical organizations now describe it the way they describe high blood pressure or type 2 diabetes: a long-term condition that is managed over years rather than fixed once. Understanding why can change how you think about treatment, and it can take some of the blame out of the conversation.
A chronic disease is a long-lasting condition that changes how the body works and usually needs ongoing care. Obesity has been described this way for a long time. A 2025 commission published in The Lancet Diabetes and Endocrinology notes that the World Health Organization first recognized obesity as a disease in 1948, and that the current international disease classification labels it "a chronic complex disease."
In the United States, the turning point came in June 2013, when the American Medical Association adopted policy that "recognizes obesity as a disease requiring a range of medical interventions to advance obesity treatment and prevention." That decision changed the framing: obesity became something clinicians are expected to assess and treat.
The condition is also common. The CDC reports that 41.9 percent of US adults had obesity in the 2017 to March 2020 survey period, up from 30.5 percent in 1999 to 2000, and that severe obesity rose from 4.7 percent to 9.2 percent over the same span.
The strongest argument for the chronic disease model comes from what happens after weight loss. Body weight is regulated by signals between the gut, fat tissue and the brain, and those signals respond to weight loss by encouraging regain.
A widely cited 2011 study in the New England Journal of Medicine followed 50 adults with overweight or obesity through a 10-week very-low-energy diet. Participants lost an average of 13.5 kg. Afterward, levels of several appetite-related hormones had shifted: leptin, peptide YY, cholecystokinin and insulin went down, while ghrelin (a hormone that stimulates hunger) went up. Participants also reported more hunger.
The key finding was timing. One year after the initial weight loss, many of these hormone changes and the increase in hunger were still present. The authors concluded that the circulating signals that encourage weight regain "do not revert to the levels recorded before weight loss," and that long-term strategies may be needed to prevent relapse. Our article on weight plateaus covers the energy-balance side of this.
Eating and activity patterns matter, but they are only part of the picture. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) lists a broad set of factors that affect weight:
The 2025 Lancet commission reached a similar conclusion, agreeing with 95 percent consensus that "genetic, environmental, psychological, nutritional and metabolic factors" can all contribute. The commission also called weight bias and stigma "major obstacles" to prevention and treatment, and said public health strategies should rest on evidence "rather than unproven assumptions that blame individual responsibility."
One criticism of calling obesity a disease is that some people with a high BMI are, by every measure, healthy. The 2025 commission, written by 58 experts and endorsed by more than 76 organizations, tried to address this directly with two categories:
| Term | What it means | Suggested approach |
|---|---|---|
| Preclinical obesity | Excess body fat with normal function of other tissues and organs, plus a generally increased risk of future illness | Health counseling, monitoring over time, and intervention when risk is higher |
| Clinical obesity | A chronic, systemic illness in which excess body fat is already changing how organs or the whole body function, or limiting daily activities | Timely, evidence-based treatment aimed at improvement or remission |
The commission also recommended that BMI alone should not be used to diagnose an individual. Excess body fat should be confirmed with a waist-based measurement or direct body fat measurement, except at very high BMI (above 40). Our guide to BMI, waist size and body fat explains those measurements.
This framing moves the question from "what is your weight?" to "how is your body fat affecting your health?"
If obesity behaves like a chronic disease, then stopping treatment should allow it to come back, the same way blood pressure rises again when blood pressure medication is stopped. Trial data support this.
In the STEP 1 trial extension, adults who had taken semaglutide for 68 weeks lost an average of 17.3 percent of their body weight. One year after semaglutide and the trial's lifestyle program ended, they had regained about two-thirds of that loss, and most of the improvements in heart and metabolic risk factors had moved back toward baseline. The authors wrote that the findings "confirm the chronicity of obesity" and suggest ongoing treatment is needed to maintain the benefits. These are group averages; individual results vary.
NIDDK guidance says the same thing in plainer terms: you will probably regain some weight after stopping weight management medication, and healthy eating and activity habits may help limit that regain. For more on planning for the long run, see ongoing weight management.
Treating obesity as a chronic disease changes the plan in a few practical ways:
GLP-1 medications such as semaglutide and tirzepatide are one option within this model. FDA-approved versions exist for chronic weight management. Compounded semaglutide and tirzepatide, including those available through NewDay Wellness, are not FDA-approved, and the FDA does not review them for safety, effectiveness or quality before they are dispensed. Dosing for any of these medications is set by the prescriber.
It is both, depending on how it affects a given person. The 2025 Lancet commission describes preclinical obesity as excess body fat with a raised risk of future illness, and clinical obesity as an illness already affecting organ function or daily life. The American Medical Association has recognized obesity as a disease since 2013.
No. The commission suggests that preclinical obesity generally does not require drugs or surgery and may be managed with counseling and monitoring. Whether medication makes sense depends on your health, history and goals, which a licensed provider can assess with you.
Research shows that after weight loss, hunger hormones shift toward regain and can stay shifted for at least a year. Trials of GLP-1 medications also show regain after the medication is stopped. This is biology, not a lack of effort.
Not necessarily forever, but most people should plan for long-term management of some kind. That might mean ongoing medication, a maintenance plan built around nutrition and activity, or a combination. Your plan can change over time with your prescriber's input.
The research summarized here offers a more accurate picture than "just use more willpower." A licensed provider can look at your measurements, lab results, health history and goals and help you decide what long-term management could look like for you. You can also start with our BMI calculator as one data point. This article is educational and does not determine eligibility for any treatment.
Written by the NewDay Wellness editorial team from the sources above and checked against them before publication, and medically reviewed by Dr. Sean Arora and Dr. Shannon Arora of Arora Health & Aesthetics; see our editorial standards. This article is educational and does not diagnose conditions, establish eligibility for any medication, or replace care from a licensed provider. Compounded medications are not FDA-approved.
Prediabetes means blood sugar is above normal but below the type 2 diabetes range, usually an A1C of 5.7 to 6.4 percent. Lifestyle change is the proven first step, and GLP-1 trials show added benefit in people who also have obesity.
Read articleResistance training is the single most effective way to protect muscle and bone while losing weight. Here is what the guidelines recommend, what the research shows, and how to begin safely without a gym background.
Read articleBoth are weekly injectables that act on gut hormone receptors, but they are not the same molecule. Here is how they differ in mechanism, trial results, side effects and regulatory status.
Read article